The PIONEER consortium was established in January 2018 and will run for a period of 5 years. We are determined to empower meaningful improvement, through the utilisation of Big Data technologies in: clinical practice; prostate cancer disease-related outcomes both clinical- and patient-specific; and health-economic outcomes across the European healthcare landscape. PIONEER brings together 32 key stakeholders in prostate cancer research and clinical care from across 9 countries. Consortium members are drawn from academic institutions, European organisations, patient advocacy groups, clinicians, and pharmaceutical companies, as well as regulatory agencies, experts in legal data management, economics and ethics, and information and technology specialists.Coordinator (EAU) & Co-Coordinators
Leader (Bayer) & Co-Leads
Partners
Contact us here
PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
